Bioinformatic Pipeline for Conserved Epitope Identification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for identifying epitopes are limited in characterizing conserved B-cell and MHC binding peptides across multiple strains of microorganisms and cells, particularly for vaccine development and therapeutic applications, as they often focus on immunodominant but variable epitopes, and fail to account for the diversity of microbial strains and cancer cells.
Innovation Solution
A method for predicting and characterizing peptides that are likely to stimulate humoral and cell-mediated immune responses by analyzing amino acid sequences using multiple predictive tools to identify B-cell and MHC binding regions, incorporating principal component analysis and neural networks to determine binding affinity, allowing for the identification of conserved epitopes across strains.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current epitope identification methods focus on immunodominant epitopes, then antibody response is improved, but conserved epitope characterization across multiple strains is lost
Solution Approach 1:
The method segments the epitope identification process into multiple independent prediction stages: B-cell epitope prediction, MHC binding prediction, and conserved region analysis. Each stage evaluates different aspects of epitope characteristics, allowing comprehensive characterization that balances immunodominance with conservation across microbial strains
Solution Approach 2:
The bioinformatic pipeline serves multiple functions simultaneously: it identifies immunodominant B-cell epitopes for antibody response, predicts MHC binding peptides for T-cell response, and characterizes conserved regions across strains. This multi-functional approach resolves the contradiction by providing a unified framework that captures both immunodominant and conserved epitope features
2Productivity
If reverse vaccinology identifies proteins from genome, then rapid epitope identification is achieved, but B-cell epitope detection coverage is limited to 25-75%
Solution Approach 1:
The method merges multiple predictive tools and algorithms into a single integrated bioinformatic pipeline. By combining B-cell epitope prediction, MHC binding prediction, and conserved region analysis, the system achieves comprehensive epitope identification that overcomes the limitations of individual methods and captures a higher proportion of true B-cell epitopes
Solution Approach 2:
The pipeline incorporates iterative refinement where prediction results from one stage inform subsequent stages. The system uses feedback loops to adjust prediction parameters and refine epitope candidates, improving detection accuracy while maintaining rapid processing through optimized computational workflows
3Object-affected harmful factors
If broad spectrum antibiotics are used, then bacterial infections are treated, but antimicrobial resistance develops
Solution Approach 1:
The method identifies strain-specific and species-specific conserved epitopes that can be targeted for highly specific antimicrobial interventions. By focusing on local, conserved regions within specific pathogens rather than broad-spectrum approaches, the system enables targeted therapies that minimize selective pressure on commensal flora and reduce resistance development
4Measurement precision
If monoclonal antibody production identifies epitopes, then specific epitopes are characterized, but less dominant conserved epitopes are underrepresented
Solution Approach 1:
The bioinformatic pipeline performs preliminary in silico screening of all potential B-cell epitopes and MHC binding peptides across the proteome before experimental validation. This preliminary action identifies both dominant and less dominant conserved epitopes, ensuring comprehensive coverage that would be missed by traditional monoclonal antibody approaches that only capture immunodominant regions
Data Source
AI summary
This invention relates to the identification of peptide binding to ligands, and in particular to identification of epitopes expressed by microorganisms and by mammalian cells. The present invention provides polypeptides comprising the epitopes, and vaccines, antibodies and diagnostic products that utilize or are developed using the epitopes.